Detection and clinical analysis of human coronavirus infection in pediatric patients with acute respiratory tract infection in the Xiamen Area, China, 2022-2024

2022-2024年中国厦门地区急性呼吸道感染患儿中人冠状病毒感染的检测和临床分析

阅读:5

Abstract

OBJECTIVE: This study aimed to investigate the prevalence of human coronavirus (HCoV) infection among pediatric patients with acute respiratory tract infection (ARTI) and to analyze the associated clinical features. METHODS: A total of 15,281 pediatric patients diagnosed with ARTI admitted to Xiamen Children’s Hospital between January 2022 and June 2024 were included in this study. Clinical symptoms and signs in HCoV-positive patients were analyzed and compared with those of patients with respiratory syncytial virus (RSV) infection during the same period. RESULTS: HCoV was detected in 147 of 15,281 patients, corresponding to a detection rate of 0.93%. Annual detection rates were 0.87% (54/6,230) in 2022, 0.82% (53/6,439) in 2023, and 1.53% (40/2,612) in 2024. Detection rates were highest in autumn and winter, peaking in November (1.89%). Of the 147 cases, 80 involved HCoV mono-infection, while 67 were co-infected with other respiratory viruses. The most common HCoV-associated clinical manifestations were cough, fever, and wheezing. The incidence of wheezing was higher in the RSV group compared to the HCoV group (p < 0.05). No statistically significant differences were observed between the two groups regarding other symptoms, complications, or the proportion of cases requiring mechanical ventilation (p > 0.05). CONCLUSIONS: The HCoV detection rate among pediatric patients with ARTI in Xiamen between January 2022 and June 2024 was 0.96%. The clinical manifestations and severity of HCoV-associated ARTI were comparable to those of RSV infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-026-12812-x.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。